Clinical trial · Interventional
Integrative Molecular Analysis of Individual Radiosensitivity in Pediatric Oncology
NCT06033183CI-TRIAL-00082918FOCUSOrecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Analysis of the individual radiosensitivity in pediatric oncology
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pediatric Cancer | Childhood Malignant Neoplasm | ALIAS | 0.90 |
| Radiation Toxicity | — | UNRESOLVED | — |
| Radiosensitivity | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sample | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Radiosensitivity
- description
- Patients who agree to participate in this research study will have blood sample collected to perform the RadioDtect test
- interventionNames
- Biological: Blood sample
Primary outcomes (2)
- measure
- Prospectively validate the discriminating capacities of the RadioDtect© individual radiosensitivity blood test on the occurrence of early radio-induced toxicities.
- timeFrame
- 24 months
- description
- The validation will be based on ATM protein quantification assay to predict acute toxicities
- measure
- Prospectively validate the discriminating capacities of the RadioDtect© individual radiosensitivity blood test on the occurrence of early radio-induced toxicities.
- timeFrame
- 24 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 3 Years
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Minor patient treated for a brain tumor, Ewing tumor, malignant mesenchymal tumor, neuroblastoma, nephroblastoma, Hodgkin's lymphoma treated with radiotherapy (+/- chemotherapy) for curative purposes. * Children or adolescents \> 3 years old and \< 18 years old * Patient with an indication for radiotherapy as part of the primary tumor local control strategy * Theoretical indication for radiotherapy in standard fractionation (1.8 Gy to 2.2 Gy / fraction: 5 fr/week) whatever the technique and the particle used * Patient affiliated with a social security scheme * Patient and/or parents or holders of parental authority having dated and signed an informed consent Exclusion criteria: * Patients with contraindications to blood sampling * Patients with contraindications to radiotherapy * Palliative radiotherapy * Patient with previous RT treatment in the same area (re-irradiation) * Patient with an indication of hypofractionated RT * Patient follow-up not possible * Persons deprived of liberty or under guardianship (including curatorship) Exclusion Criteria: \-
References
Publications (0)
Data not yet available
No reference posted for this study.